<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathobiology of chronic lymphocytic leukemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathobiology of chronic lymphocytic leukemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathobiology of chronic lymphocytic leukemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kanti R Rai, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephan Stilgenbauer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm) characterized by the progressive accumulation of functionally incompetent lymphocytes, which are usually monoclonal in origin.
        </p>
        <p>
         CLL is considered to be identical (ie, one disease with different manifestations) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL), a clinically indolent non-Hodgkin lymphoma. The term CLL is used when the disease manifests primarily in the blood, whereas the term SLL is used when involvement is primarily nodal.
        </p>
        <p>
         The pathogenesis and disease evolution of CLL/SLL will be reviewed here. The clinical manifestations, diagnosis, staging, prognosis, and treatment of CLL/SLL are discussed separately, as is the related condition monoclonal B cell lymphocytosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">
          "Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">
          "Overview of the treatment of chronic lymphocytic leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118011.html" rel="external">
          "Monoclonal B cell lymphocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4346378">
         <span class="h1">
          DISEASE EVOLUTION FROM MONOCLONAL B CELL LYMPHOCYTOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of CLL/small lymphocytic lymphoma (SLL) is a complex, multistep process leading to the accumulation of monoclonal, mature, functionally incompetent B lymphocytes in the peripheral blood, bone marrow, lymph nodes, and spleen  (
         <a class="graphic graphic_figure graphicRef85975" href="/z/d/graphic/85975.html" rel="external">
          figure 1
         </a>
         ). This evolution can be conceptualized as a sequential process, with a minority of cases progressing at each step:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishment of MBL
         </strong>
         – CLL/SLL is preceded by an asymptomatic premalignant B cell proliferative disorder known as monoclonal B cell lymphocytosis (MBL), defined by a monoclonal population of B lymphocytes &lt;5000 cells/microL (&lt;5 x 10
         <sup>
          9
         </sup>
         /L) in the peripheral blood, with a CLL/SLL phenotype, without other features of a B cell lymphoproliferative disorder (eg, lymphadenopathy, organomegaly, cytopenias, or extramedullary involvement).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MBL with a CLL/SLL phenotype is present in 5 to 10 percent of persons over age 60 and a smaller percentage of younger persons [
         <a href="#rid1">
          1,2
         </a>
         ]. High-count CLL-like MBL (&gt;2000 cells/microL [&gt;2 x 10
         <sup>
          9
         </sup>
         /L] with a CLL phenotype) progresses to CLL/SLL at a rate of approximately 1 to 2 percent per year [
         <a href="#rid3">
          3,4
         </a>
         ]. While the inciting event is unknown, the development of MBL likely reflects a combination of factors, including antigenic stimulation, changes in the bone marrow microenvironment, genetic changes, and epigenetic modification. (See
         <a class="medical medical_review" href="/z/d/html/118011.html" rel="external">
          "Monoclonal B cell lymphocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progression from MBL to asymptomatic CLL/SLL
         </strong>
         – Progression to CLL is defined by a rise in this monoclonal population of B lymphocytes with a CLL phenotype in the peripheral blood to ≥5000 cells/microL (≥5 x 10
         <sup>
          9
         </sup>
         /L). Progression of MBL to CLL/SLL is the result of further insults to the B cell clone, through genetic changes and/or changes in the bone marrow and lymph node microenvironment [
         <a href="#rid5">
          5
         </a>
         ]. A large subset of patients with CLL/SLL remains asymptomatic despite the increased number of circulating monoclonal B lymphocytes. A minority of cases regress spontaneously. (See
         <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">
          "Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progression to symptomatic CLL/SLL
         </strong>
         – Ultimately, some patients develop signs and symptoms related to the accumulation of functionally incompetent lymphocytes and suppression of normal organ function (eg, lymphadenopathy, hepatosplenomegaly, cytopenias, infections). Complex studies using next-generation sequencing suggest that an individual CLL/SLL tumor is genetically heterogeneous, with several subpopulations of malignant cells evolving over time [
         <a href="#rid6">
          6-11
         </a>
         ]. The relative contribution of each subpopulation to the total tumor volume is likely affected by interactions with other subpopulations, the tumor microenvironment, and therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evolution to more aggressive disease
         </strong>
         – Over time and under the selective pressure of therapy, clonal evolution can result in CLL/SLL that is more aggressive and resistant to treatment. In addition, a minority of cases will undergo histologic transformation to a more aggressive lymphoproliferative disorder, such as diffuse large B cell lymphoma (also known as Richter transformation). (See
         <a class="local">
          'Histologic transformation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          THE CLL CELL
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Cell of origin
         </span>
         <span class="headingEndMark">
          —
         </span>
         While CLL/small lymphocytic lymphoma (SLL) cells look like mature small lymphocytes seen in the peripheral blood of normal individuals, they are functionally incompetent clonal B cells arrested in the B cell differentiation pathway at some intermediate stage between the pre-B cell and mature B cell, perhaps in the "activated, antigen-experienced" B cell subset [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p>
         Specific subsets of CD5+ B cells may be the normal counterparts of CLL/SLL [
         <a href="#rid15">
          15-17
         </a>
         ]. Studies using gene expression profiling suggest that the cell of origin likely differs between cases with and without mutated immunoglobulin heavy chain variable region (IGHV) genes [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL/SLL with unmutated IGHV – Expression resembles that of pre-germinal center (unmutated) mature CD5+ B cells; cells are polyreactive and clinically more aggressive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL/SLL with mutated IGHV – Expression resembles that of CD5+CD27+ post-germinal center B cells; cells have a narrow antigen specificity (more anergic) and are clinically less aggressive.
        </p>
        <p>
        </p>
        <p>
         Several studies have evaluated the pathophysiologic implications of the combination of cell surface markers seen in CLL/SLL. CD5+ B cells with many or all of the characteristics of CLL/SLL cells, including monoclonality, can be found in the lymph nodes and spleen of the normal human fetus, and at the edge of germinal centers of lymph nodes [
         <a href="#rid19">
          19-21
         </a>
         ], as well as in the peripheral blood of normal adults [
         <a href="#rid22">
          22,23
         </a>
         ]. In addition, approximately 15 percent of normal B cells in the peripheral blood express CD5 [
         <a href="#rid24">
          24
         </a>
         ]. A minor subpopulation of normal human CD5+ cells is considered to be a long-lived population circulating between blood and lymph nodes, mostly located in the inner layer of mantle zones; these cells may be the normal counterpart of the neoplastic CLL/SLL cells [
         <a href="#rid25">
          25
         </a>
         ]. The most frequent CLL/SLL phenotype corresponds to one or more cellular subsets within the mantle zone of lymph nodes.
        </p>
        <p>
         Evaluation of a naturally occurring CD5+ B cell subset that resembles autoantibody-producing CLL/SLL cells showed a restricted expression of IGHV genes [
         <a href="#rid26">
          26
         </a>
         ], raising the possibility that CLL/SLL may arise from a normal B cell subset engaged in autoantibody production [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H241998986">
         <span class="h2">
          Cellular proliferation
         </span>
         <span class="headingEndMark">
          —
         </span>
         CLL/SLL cells can exhibit impaired apoptosis and increased proliferation. The kinetic balance between these impacts disease tempo.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired apoptosis
         </strong>
         – Initially, it was thought that the majority of CLL/SLL cells were in the G(0) phase of the cell cycle, with &lt;1 percent spontaneous mitoses in vitro, suggesting that CLL/SLL was a disease of accumulation of long-lived lymphocytes. Indeed, malignant cells accumulate in CLL/SLL at least partly due to their inability to undergo apoptosis. Mechanisms of apoptosis resistance in CLL/SLL include overexpression of B cell leukemia/lymphoma 2 (BCL2) and Fas-inhibitory molecules such as TOSO [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Upregulation of BCL2 proto-oncogene'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased proliferation
         </strong>
         – In vivo kinetic studies have uncovered a wide range of cellular proliferation and death rates among individual patients. Some exhibit exponential growth with short lymphocyte doubling times and rapidly progressive disease, while others demonstrate a logistic growth which slows and stabilizes as the population size reaches its maximum capacity [
         <a href="#rid29">
          29,30
         </a>
         ]. Those patients with higher proliferation rates are much more likely to exhibit active disease or develop progressive disease than those with lower proliferation rates [
         <a href="#rid31">
          31,32
         </a>
         ]. Proliferation is impacted by genetic features (eg, IGHV mutation status), B cell receptor signaling, and interactions with the tumor microenvironment and/or antigens [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="local">
          'Antigen-independent BCR signaling'
         </a>
         below and
         <a class="local">
          'Tumor microenvironment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2803868328">
         <span class="h2">
          Defective B and T cell function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CLL/SLL have abnormal cellular and humoral-mediated immune responses due to qualitative and quantitative defects in immune effector cells. In addition, a subset experience autoimmune phenomena.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypogammaglobulinemia
         </strong>
         – Hypogammaglobulinemia is present in approximately 25 percent of patients at the time of initial diagnosis and may develop in up to two-thirds of patients later in the course of the disease [
         <a href="#rid35">
          35
         </a>
         ]. Hypogammaglobulinemia is thought to be related to defective functioning of T cells and non-clonal CD5-negative B cells. (See
         <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">
          "Risk of infections in patients with chronic lymphocytic leukemia", section on 'Humoral immunity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Defective antibody response
         </strong>
         – Patients with CLL/SLL may have defective antibody responses to specific infections and immunizations [
         <a href="#rid36">
          36
         </a>
         ]. Treatment-naïve patients are at increased risk for bacterial infections caused by common pathogens, such as
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Klebsiella pneumoniae
         </em>
         , and
         <em>
          Pseudomonas aeruginosa
         </em>
         [
         <a href="#rid37">
          37
         </a>
         ]. Response to immunizations is suboptimal due to impaired antibody production and defects in antigen presentation. (See
         <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">
          "Risk of infections in patients with chronic lymphocytic leukemia", section on 'Spectrum of infections'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Immunizations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune disorders
         </strong>
         – Autoimmune disorders occur in up to 25 percent of patients, depending on the disease phase [
         <a href="#rid17">
          17,38
         </a>
         ]. These include Coombs-positive autoimmune hemolytic anemia, immune thrombocytopenia (ITP), pure red cell aplasia, and autoimmune granulocytopenia [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4504.html" rel="external">
          "Overview of the complications of chronic lymphocytic leukemia", section on 'Autoimmune hemolytic anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The development of autoimmune phenomena in patients with CLL/SLL is likely a complex process that involves the malignant B cells, residual polyclonal B cells, and T cells in the tumor microenvironment, and multiple mechanisms may be involved. Interactions between the malignant B cells and residual normal B cells can lead to the production of polyclonal high-affinity immunoglobulin directed against antigens on red blood cells and platelets [
         <a href="#rid41">
          41
         </a>
         ]. In addition, in approximately 25 percent of CLL/SLL cases bearing kappa light chains on the lymphocyte surface, the leukemic cells react against an anti-idiotype antibody to a highly conserved region of one specific kappa gene (cross-reactive idiotype) [
         <a href="#rid15">
          15-17
         </a>
         ]. Alterations in the T cell compartment likely also contribute to autoimmune phenomena. Further insight may be gained by studying other patients with autoimmune disorders. In one study, CD5+ B cells were increased in patients with autoimmune disorders, such as rheumatoid arthritis [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1140771053">
         <span class="h2">
          BCR stereotypy
         </span>
         <span class="headingEndMark">
          —
         </span>
         CLL/SLL cells express B cell antigen receptors (BCRs) with a limited immunoglobulin repertoire characterized by restricted heavy and light chain usage (referred to as BCR stereotypy).
        </p>
        <p>
         In large-scale studies that have sequenced these immunoglobulins in unrelated patients with CLL/SLL, &gt;20 percent of cases have near identical immunoglobulin sequences in the heavy variable complementarity determining region 3 (VH CDR3) [
         <a href="#rid43">
          43-53
         </a>
         ]. The similarity of these BCRs is significantly greater than that which would be expected based on chance alone. BCR stereotypy is more common in clinically aggressive CLL/SLL with unmutated IGHV genes.
        </p>
        <p>
         BCR stereotypy in CLL/SLL cases suggests a role for antigens in the pathogenesis and evolution of CLL/SLL. BCR stereotypes can also be used to group CLL/SLL cases into subsets with presumably different biological backgrounds, prognosis, and response to treatment [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H422760193">
         <span class="h1">
          GENETIC ABNORMALITIES
         </span>
        </p>
        <p class="headingAnchor" id="H1846204069">
         <span class="h2">
          Genomic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic abnormalities are present in the vast majority of CLL/small lymphocytic lymphoma (SLL) tumors at diagnosis, and additional genetic abnormalities are acquired with disease evolution [
         <a href="#rid55">
          55,56
         </a>
         ]. While the significance of many of these abnormalities is unclear, some are prognostic and a few impact treatment decisions. The role of genetic abnormalities on pathogenesis is discussed here. Their impact on prognosis and treatment decisions is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83749.html" rel="external">
          "Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Choice of therapy'
         </a>
         .)
        </p>
        <p>
         At least one of four common chromosomal abnormalities can be detected by interphase fluorescence in situ hybridization (FISH) in approximately 80 percent of CLL/SLL tumors [
         <a href="#rid57">
          57-59
         </a>
         ]. The cytogenetic abnormalities appear to be restricted to B cells in CLL/SLL [
         <a href="#rid60">
          60
         </a>
         ]. Given the frequency of these abnormalities, studies have evaluated their potential impact on pathogenesis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Del(13q14)
         </strong>
         – Del(13q14) is detected in 50 to 60 percent of CLL/SLL tumors. The deleted region contains miR15A and miR16A micro-ribonucleic acid (micro-RNA) [
         <a href="#rid61">
          61
         </a>
         ]. These micro-RNA regulate the expression of proteins involved in apoptosis and the cell cycle. Deletion of these micro-RNA leads to the development of CLL/SLL in mouse models [
         <a href="#rid62">
          62
         </a>
         ]. Without them, the cells do not respond appropriately to stress signals that should induce apoptosis. The B cell leukemia/lymphoma 2 (
         <em>
          BCL2
         </em>
         ) gene encodes the antiapoptotic protein BCL2 and is one of the genes upregulated when these micro-RNA are deleted [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Upregulation of BCL2 proto-oncogene'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trisomy 12
         </strong>
         – Trisomy 12 is detected in 10 to 20 percent of CLL/SLL tumors. CLL/SLL with trisomy 12 has a gene expression profile that includes overexpression of RUNX3 [
         <a href="#rid63">
          63
         </a>
         ]. Further details on whether trisomy 12 impacts CLL/SLL development and evolution are unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Del(11q22-23)
         </strong>
         – Del(11q22-23) is detected in 10 to 20 percent of CLL/SLL tumors at diagnosis. The deleted region contains the ataxia telangiectasia (
         <em>
          ATM
         </em>
         ) gene. The ATM gene product is involved in the detection of deoxyribonucleic acid (DNA) damage and plays an important role in cell cycle progression. CLL/SLL cells without normal ATM function are unable to respond appropriately to chemotherapy-induced DNA damage. (See
         <a class="local">
          'Impaired DNA damage response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Del(17p12)
         </strong>
         – Del(17p12) is detected in 4 to 10 percent of CLL/SLL tumors at diagnosis and a larger percentage at relapse. The deleted region contains the
         <em>
          TP53
         </em>
         gene, which is essential for a normal DNA damage response leading to apoptosis. CLL/SLL cells without normal TP53 function, either through del(17p12) or through
         <em>
          TP53
         </em>
         mutation, cannot trigger apoptosis in response to chemotherapy-induced DNA damage. (See
         <a class="local">
          'Impaired DNA damage response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In addition, abnormalities in certain genes have been identified in patients with CLL/SLL with or without the presence of chromosomal abnormalities. As described above, CLL/SLL with
         <em>
          TP53
         </em>
         mutations are unable to respond appropriately to chemotherapy-induced DNA damage. Other gene mutations have been found that impact signaling pathways within the cell (involved in DNA damage response, the cell cycle, RNA splicing and metabolism, and chromatin modifiers) and those involved in microenvironment dependent signaling (NOTCH1 signaling, BCR and Toll-like receptor signaling, MPK-ERK pathway signaling, NF-kB signaling) [
         <a href="#rid8">
          8,9,64,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1566378412">
         <span class="h2">
          Gene mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complex studies using next-generation sequencing have shown that an individual CLL/SLL tumor is genetically heterogeneous, with several subpopulations of malignant cells evolving over time [
         <a href="#rid6">
          6-10
         </a>
         ]. Most CLL/SLL tumors have thousands of somatic gene mutations. Of these, four are present at diagnosis in &gt;5 percent of patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          TP53
         </em>
         – TP53 activity is essential for a normal DNA damage response leading to apoptosis. CLL/SLL cells without normal TP53 function cannot trigger apoptosis in response to chemotherapy-induced DNA damage. (See
         <a class="local">
          'Impaired DNA damage response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          ATM
         </em>
         –
         <em>
         </em>
         The ATM gene product is involved in the detection of DNA damage and plays an important role in cell cycle progression. CLL/SLL cells without normal ATM function are unable to respond appropriately to chemotherapy-induced DNA damage. Rare germline
         <em>
          ATM
         </em>
         variants appear to be more common in patients with CLL/SLL than in those with other hematologic disorders, and patients with CLL and a germline
         <em>
          ATM
         </em>
         variant are more likely than others to have
         <em>
          ATM
         </em>
         -aberrant CLL/SLL (ie, 11q deletion or somatic mutation in
         <em>
          ATM
         </em>
         ) [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="local">
          'Impaired DNA damage response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          NOTCH1
         </em>
         – Notch proteins are transmembrane receptors that are involved in regulating hematopoietic cell development. A subset of CLL/SLL tumors have activating mutations in coding and noncoding regions of the
         <em>
          NOTCH1
         </em>
         proto-oncogene, causing aberrant splicing events, increased NOTCH1 activity, and more aggressive disease [
         <a href="#rid8">
          8,67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia", section on 'NOTCH1 mutations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          SF3B1
         </em>
         – The
         <em>
          SF3B1
         </em>
         gene encodes for part of a nuclear ribonucleoprotein that complexes with other nuclear ribonucleoproteins to create the spliceosome that is responsible for splicing messenger RNA.
         <em>
          SF3B1
         </em>
         mutations can be identified in a subset of patients with CLL/SLL and are associated with a poor prognosis [
         <a href="#rid9">
          9,64,68-71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia", section on 'SF3B1 mutations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Many of the other mutations seen in CLL/SLL tumors are involved in a limited number of cellular signaling pathways [
         <a href="#rid6">
          6-10,65
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microenvironment dependent signaling
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Notch signaling (eg,
         <em>
          NOTCH1
         </em>
         ,
         <em>
          FBXW7
         </em>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         BCR and Toll-like receptor signaling (
         <em>
          BCOR
         </em>
         ,
         <em>
          KLHL6
         </em>
         ,
         <em>
          PAX5
         </em>
         ,
         <em>
          IRF4
         </em>
         ,
         <em>
          CARD11
         </em>
         ,
         <em>
          TLR2
         </em>
         ,
         <em>
          MYD88
         </em>
         ,
         <em>
          IRAK1
         </em>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MAPK-ERK pathway (
         <em>
          KRAS
         </em>
         ,
         <em>
          NRAS
         </em>
         ,
         <em>
          PTPN11
         </em>
         ,
         <em>
          GNB1
         </em>
         ,
         <em>
          BRAF
         </em>
         ,
         <em>
          MAP2K1
         </em>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         NF-kB signaling (
         <em>
          TRAF3
         </em>
         ,
         <em>
          TRAF2
         </em>
         ,
         <em>
          BIRC3
         </em>
         ,
         <em>
          EGR2
         </em>
         ,
         <em>
          NRKBIE
         </em>
         ,
         <em>
          NKAP
         </em>
         ,
         <em>
          NFKB2
         </em>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracellular signaling
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chromatin modifiers (
         <em>
          CHD2
         </em>
         ,
         <em>
          SETD2
         </em>
         ,
         <em>
          ZMYM3
         </em>
         ,
         <em>
          KMT2D
         </em>
         ,
         <em>
          SETD1A
         </em>
         ,
         <em>
          ASXL1
         </em>
         ,
         <em>
          ARID1A
         </em>
         ,
         <em>
          BAZ2A
         </em>
         ,
         <em>
          HIST1H1B
         </em>
         ,
         <em>
          HIST1H1E
         </em>
         ,
         <em>
          SYNE1
         </em>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cell cycle (
         <em>
          ATM
         </em>
         ,
         <em>
          TP53
         </em>
         ,
         <em>
          MGA
         </em>
         ,
         <em>
          CCND2
         </em>
         ,
         <em>
          CCKN1B
         </em>
         ,
         <em>
          CDKN2A
         </em>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DNA damage (
         <em>
          ATM
         </em>
         ,
         <em>
          TP53
         </em>
         ,
         <em>
          POT1
         </em>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RNA splicing and metabolism (
         <em>
          SF3B1
         </em>
         ,
         <em>
          U1
         </em>
         ,
         <em>
          DDX3X
         </em>
         ,
         <em>
          XPO1
         </em>
         ,
         <em>
          RPS15
         </em>
         ,
         <em>
          ZNF292
         </em>
         ,
         <em>
          NXF1
         </em>
         ,
         <em>
          MED12
         </em>
         ,
         <em>
          FUBP1
         </em>
         ,
         <em>
          CNOT3
         </em>
         )
        </p>
        <p>
        </p>
        <p>
         Mutational burden and frequency of driver mutations differ between cases with and without mutated immunoglobulin heavy chain variable region (IGHV) genes [
         <a href="#rid8">
          8,9,65
         </a>
         ]. In addition, some specific mutations are primarily seen in one of these groups, while other mutations are seen in both mutated and unmutated CLL/SLL.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL/SLL with unmutated IGHV – These more clinically aggressive tumors have a lower average mutational burden (approximately 2000 somatic mutations) but a greater frequency of driver mutations. Mutations in
         <em>
          U1
         </em>
         ,
         <em>
          NOTCH1
         </em>
         , and
         <em>
          POT1
         </em>
         are primarily seen in this group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL/SLL with mutated IGHV – These clinically less aggressive tumors have a higher average mutational burden (approximately 3000 somatic mutations) but a lower frequency of driver mutations. Mutations in
         <em>
          MYD88
         </em>
         and
         <em>
          PAX5
         </em>
         are predominantly seen in this group.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H497391265">
         <span class="h2">
          Micro-RNA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Micro-RNAs are a class of small noncoding RNAs that modulate the expression of genes at the post-transcriptional level and are involved in cancer, apoptosis, and cell metabolism [
         <a href="#rid72">
          72
         </a>
         ]. They appear to interact with BCL2 and TP53 in CLL/SLL and may be important in the pathogenesis [
         <a href="#rid73">
          73,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia", section on 'Other markers'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mutations in micro-RNA transcripts are frequent, some of them germline, and may predispose to CLL/SLL and to a spectrum of associated malignancies [
         <a href="#rid75">
          75-77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 56 patients with CLL/SLL, marked overexpression of two micro-RNAs (miR21 and miR155) was seen in almost every sample analyzed [
         <a href="#rid78">
          78
         </a>
         ]. In a larger subsequent study, when compared with normal controls, plasma miR155 levels were significantly increased in patients with monoclonal B cell lymphocytosis and further increased in patients with CLL/SLL [
         <a href="#rid79">
          79
         </a>
         ]. In this study, increased miR155 expression was associated with more refractory disease and worse survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         miR15A and miR16A have been shown to interact directly with and result in the upregulation of the BCL2 antiapoptotic protein in many cases of CLL/SLL [
         <a href="#rid61">
          61
         </a>
         ]. These two mRNAs are deleted in CLL/SLL with 13q deletion. (See
         <a class="local">
          'Upregulation of BCL2 proto-oncogene'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         miR150 regulates the expression of genes encoding proteins that impact BCR signaling in CLL/SLL (eg, FOXP1 and GAB1) [
         <a href="#rid80">
          80
         </a>
         ]. Low levels of miR150 are associated with higher levels of FOXP1 and GAB1 and increased signaling through the B cell receptor. (See
         <a class="local">
          'Antigen-independent BCR signaling'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The expression of micro-RNA may be regulated by tumor suppressor genes or through epigenetic modification. As an example, the expression of a micro-RNA cluster located at 11q (miR34b/miR-34c) appears to be directly activated by TP53 [
         <a href="#rid81">
          81
         </a>
         ]. In contrast, increased histone deacetylase activity appears to downregulate the expression of other micro-RNAs (eg, miR15a, miR16, miR29b), resulting in decreased apoptosis [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="local">
          'Impaired DNA damage response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H198981162">
         <span class="h1">
          ABERRANT SIGNALING PATHWAYS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As described above, genetic studies have revealed several major cellular signaling pathways that may be involved in the development and/or evolution of CLL/small lymphocytic lymphoma (SLL). Of these, pathways that are key to understanding the biology from a clinical perspective include antigen-independent B cell receptor (BCR) signaling, upregulation of the antiapoptotic factor B cell leukemia/lymphoma 2 (BCL2), and impaired DNA damage response.
        </p>
        <p class="headingAnchor" id="H25649455">
         <span class="h2">
          Antigen-independent BCR signaling
         </span>
         <span class="headingEndMark">
          —
         </span>
         BCR activation is a key feature of CLL/SLL and therapeutic target. CLL/SLL tumor cells express BCRs with a restricted repertoire of mutations that result in antigen-dependent and antigen-independent cell-autonomous signaling [
         <a href="#rid83">
          83
         </a>
         ]. BCR signaling directs many cellular processes including growth, differentiation, survival, and adhesion or cellular migration. The processes impacted in a specific cell depend upon cellular maturation, the antigen ligated, and the microenvironment.
        </p>
        <p>
         In CLL/SLL cells, constitutive activation of BCR results in increased expression of SYK, LYN, BTK, and PI3K kinase [
         <a href="#rid84">
          84
         </a>
         ]. This increased signaling activates the cytoplasmic domain of an integrin, and it causes a conformation change that increases its affinity for ligand binding. Binding of a ligand to the integrin's extracellular domain results in intracellular signals that promote growth, survival, differentiation, and migration.
        </p>
        <p>
         The interaction between CLL/SLL tumor cells and antigens is influenced by the somatic hypermutation load of the immunoglobulin heavy chain variable region (IGHV) genes [
         <a href="#rid85">
          85,86
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL with unmutated IGHV – Cells are polyreactive, capable of binding multiple epitopes that can result in sustained BCR signaling. Clones expand more rapidly, and the clinical course is more aggressive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CLL with mutated IGHV – Cells have narrow antigen specificity (anergic) and dampened BCR signaling. Clones expand more slowly, and the clinical course is more indolent.
        </p>
        <p>
        </p>
        <p>
         miR150 micro-RNA regulates the expression of genes encoding proteins that impact BCR signaling in CLL/SLL (eg, FOXP1 and GAB1) [
         <a href="#rid80">
          80
         </a>
         ]. Low levels of miR150 are associated with higher levels of FOXP1 and GAB1, and increased BCR signaling. (See
         <a class="local">
          'Micro-RNA'
         </a>
         above.)
        </p>
        <p>
         Mutations within the BCR pathway are uncommon at the time of CLL diagnosis. However, a percentage of CLL/SLL tumors that progress on BCR inhibitor therapy will have mutations in the target. (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia", section on 'BTK, PLCg2, and BCL2 mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2046014529">
         <span class="h2">
          Upregulation of BCL2 proto-oncogene
         </span>
         <span class="headingEndMark">
          —
         </span>
         BCL2 expression is elevated in approximately 95 percent of patients with CLL/SLL. BCL2 is an antiapoptotic protein; when overexpressed, CLL cells do not respond appropriately to signals that should induce apoptosis.
        </p>
        <p>
         Unlike other lymphoid neoplasms with increased BCL2 expression (eg, follicular lymphoma), the increased expression is not due to a t(14;18) chromosomal translocation [
         <a href="#rid87">
          87,88
         </a>
         ]. Overexpression may be due to one or more mechanisms, including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deletion of miR15A and miR16A micro-RNA in CLL with del(13q14) can result in
         <em>
          BCL2
         </em>
         gene upregulation [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Genetic abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The tumor microenvironment may impact expression with higher levels seen in CLL cells derived from lymph nodes than in CLL/SLL cells derived from the peripheral blood or bone marrow [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         BCL2 is expressed in CD5+ CLL cells but not in normal CD5+ B cells. In contrast to other proto-oncogenes, BCL2 has little or no ability to promote cell cycle progression or cell proliferation, but rather raises the cellular apoptotic threshold. It suppresses apoptosis (programmed cell death), resulting in prolonged survival of the involved cells [
         <a href="#rid90">
          90
         </a>
         ]. In vitro studies have shown that CLL/SLL cells with higher levels of BCL2 protein survive longer in culture than those with lower levels [
         <a href="#rid87">
          87,91
         </a>
         ].
        </p>
        <p>
         <em>
          BCL2
         </em>
         gene mutations are uncommon at the time of CLL diagnosis. However, they can be detected in a percentage of CLL/SLL tumors that progress on BCL2-directed therapy (ie,
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4489.html" rel="external">
          "Staging and prognosis of chronic lymphocytic leukemia", section on 'BTK, PLCg2, and BCL2 mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1175836550">
         <span class="h2">
          Impaired DNA damage response
         </span>
         <span class="headingEndMark">
          —
         </span>
         At the time of diagnosis, a minority of CLL/SLL tumors will have genetic abnormalities associated with impaired DNA damage response (eg, deletion 17p,
         <em>
          TP53
         </em>
         mutation, deletion 11q). These changes become more common as the disease progresses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lost or mutated
         </strong>
         <strong>
          <em>
           TP53
          </em>
         </strong>
         – The DNA damage response is impaired in CLL with lost (deletion 17p) or mutated
         <em>
          TP53
         </em>
         . The normal "wild-type"
         <em>
          TP53
         </em>
         gene produces a DNA-binding protein that acts as a transcriptional activator of growth inhibitory genes. Wild-type
         <em>
          TP53
         </em>
         may be particularly critical when cells are under stress.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Normally, cells arrest their growth in response to DNA damaging agents and other stressors (eg, hypoxia) via induction/activation of p53 [
         <a href="#rid92">
          92-94
         </a>
         ]. Once activated, p53 induces a variety of growth-limiting responses, including cell cycle arrest (in order to facilitate DNA repair), apoptosis, senescence, and differentiation. p53 produces these responses largely by altering the expression of target genes. CLL/SLL cells with mutated or deleted
         <em>
          TP53
         </em>
         are missing this mechanism of growth arrest.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lost ATM
         </strong>
         – Chromosome 11q contains the ataxia telangiectasia mutated (
         <em>
          ATM
         </em>
         ) gene (mapped to chromosome 11q22.3). The ATM kinase is involved in a surveillance mechanism that, in the presence of DNA damage, stalls progression of the cell cycle [
         <a href="#rid95">
          95
         </a>
         ]. This delay allows the cell to repair the damage, rather than passing on inappropriate genetic information to daughter cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the presence of DNA damage, the ATM kinase phosphorylates the tumor suppressor protein p53 [
         <a href="#rid96">
          96
         </a>
         ]. Phosphorylated p53 serves as a transcriptional activator of genes that cause cell cycle arrest or apoptosis. In the absence of ATM kinase, p53 does not become phosphorylated and cannot prevent the cell from moving into the next phase of the cell cycle. (See
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia", section on 'Genetics and pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          TUMOR MICROENVIRONMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         CLL/small lymphocytic lymphoma (SLL) results in the clonal proliferation and accumulation of monoclonal, mature, CD5+ B cells in the peripheral blood, bone marrow, lymph nodes, and spleen. Clonal proliferation primarily occurs in the lymph nodes, in the complex domain of the tumor microenvironment. CLL/SLL cells both influence the composition of the cells around them, and they are highly dependent upon signals from these cells for their own survival and proliferation.
        </p>
        <p>
         In CLL/SLL, lymph nodes have "pseudofollicles" which mimic normal B cell follicles. Here, CLL/SLL cells interact with the extracellular matrix, T cells, nurse-like cells (monocyte derived macrophages), stromal follicular dendritic cells, and other stromal cells. Complex, bidirectional interactions occur through direct cell-to-cell contact and indirectly through chemokines and cytokines. CLL/SLL cells are dependent on signals from the microenvironment. Interactions with the microenvironment increase the activation of antiapoptotic and proliferation pathways [
         <a href="#rid89">
          89,97
         </a>
         ].
        </p>
        <p>
         CLL/SLL cells encourage a leukemia-supportive, immunosuppressive microenvironment [
         <a href="#rid33">
          33,98,99
         </a>
         ]. T cell impairments include reduced T cell motility, impaired CD4+ cell function, and CD8+ cell exhaustion [
         <a href="#rid100">
          100-104
         </a>
         ]. Monocytes differentiate towards leukemia-supportive macrophages [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Because B cells account for almost 90 percent of all lymphocytes in CLL/SLL, the percentages of T cells and natural killer (NK) cells are relatively decreased. While the absolute T cell count is often high, it may be normal or low. NK cells are usually decreased in number as well as function in CLL/SLL.
        </p>
        <p>
         Patients with CLL/SLL also may have an unusual T cell subpopulation expressing lower CD4 or CD8 levels than classic T cells, which may derive from nonclassic pathways of T cell development [
         <a href="#rid100">
          100,105-107
         </a>
         ] or through direct interaction with the malignant B cell population [
         <a href="#rid108">
          108
         </a>
         ]. Similar cells have been described in human and murine autoimmune disease [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3845956816">
         <span class="h1">
          HISTOLOGIC TRANSFORMATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a variable percentage of patients with CLL/small lymphocytic lymphoma (SLL), and usually as a terminal event, CLL/SLL transforms into another lymphoproliferative disorder. When compared with the general population, patients with CLL/SLL have a two- to fivefold increased risk of developing a second lymphoid malignancy [
         <a href="#rid109">
          109
         </a>
         ]. In approximately 80 percent of cases, the transformed cells are clonally related to the original CLL/SLL cells while, in the remaining 20 percent, they appear to be derived from a separate cell of origin (clonally unrelated) [
         <a href="#rid110">
          110
         </a>
         ]. The clonal relationship between these two cell populations may impact management.
        </p>
        <p>
         Transformation of CLL into a more aggressive disease is termed Richter transformation. The following are the most commonly reported transformations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive or highly aggressive lymphoma – 3 to 7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolymphocytic leukemia (PLL) – 2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin lymphoma – 0.5 to 2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple myeloma – 0.1 percent
        </p>
        <p>
        </p>
        <p>
         While transformation to multiple myeloma has been reported, most cases of multiple myeloma in patients with CLL represent a second malignancy rather than transformation.
        </p>
        <p>
         It is unknown whether targeted therapies impact the risk of histologic transformation or development of a second lymphoid malignancy. Investigation into this question is hampered by the relatively short follow-up of randomized trials evaluating these agents and trial designs that allowed for crossover to a targeted agent in those who did not attain a response to chemotherapy. The early studies of
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         and
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         in high-risk relapsed refractory patient populations showed relatively high rates of transformation [
         <a href="#rid111">
          111,112
         </a>
         ]. These high rates have not been demonstrated in subsequent randomized trials in earlier stage disease, suggesting that disease biology may play a larger role than drug exposure in determining transformation [
         <a href="#rid113">
          113-115
         </a>
         ].
        </p>
        <p>
         It is also unclear whether treatment with either a purine nucleoside analogue or an anthracycline significantly increases the risk of a second lymphoid malignancy. A potentially increased incidence was initially suggested by an observational cohort study from the Mayo Clinic that followed 962 patients with CLL/SLL for a median of 3.3 years and reported that 26 patients (2.7 percent) developed a second lymphoid malignancy [
         <a href="#rid116">
          116
         </a>
         ]. In this study, prior treatment with a purine nucleoside analog or an anthracycline was associated with a higher likelihood of developing a second lymphoid malignancy. However, this association was not confirmed in the prospective CALGB 9011 study in which 521 patients with previously untreated CLL/SLL were randomly assigned to receive
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         , or both [
         <a href="#rid117">
          117
         </a>
         ]. After a minimum follow-up of 15 years, Richter transformation developed in 34 patients (7 percent) and PLL developed in 10 patients (2 percent). The incidence of Richter transformation and PLL was independent of initial therapy.
        </p>
        <p class="headingAnchor" id="H1561670615">
         <span class="h2">
          Richter transformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 1 to 10 percent of patients, CLL/SLL transforms to a clinically aggressive lymphoma (called Richter transformation or Richter syndrome)  (
         <a class="graphic graphic_picture graphicRef53282" href="/z/d/graphic/53282.html" rel="external">
          picture 1
         </a>
         ). This transformation is often heralded by sudden clinical deterioration, characterized by increasing lymphadenopathy, splenomegaly, worsening "B" symptoms (ie, fever, night sweats, weight loss), a rapidly progressive clinical course, and increased lactate dehydrogenase (LDH). This subject is discussed in depth separately. (See
         <a class="medical medical_review" href="/z/d/html/4728.html" rel="external">
          "Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H277687155">
         <span class="h2">
          Prolymphocytoid transformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In approximately 10 percent of patients with CLL/SLL, the terminal event is a morphological transformation of blood lymphocytes from the typical small, mature-appearing cell to somewhat larger cells with distinct nucleoli and a less dense nuclear chromatin. This event, called prolymphocytoid transformation, occurs slowly over years and is associated with treatment refractory disease, although it can also be seen in the absence of therapy [
         <a href="#rid118">
          118,119
         </a>
         ]. Prolymphocytoid transformation is clinically and immunophenotypically distinct from de novo prolymphocytic leukemia. (See
         <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">
          "Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Prolymphocytic leukemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2959359370">
         <span class="h2">
          Acute leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         When acute myeloid leukemia (AML) occurs in a patient with CLL/SLL, it is most likely to be a therapy-related myeloid neoplasm or a de novo AML and
         <strong>
          not
         </strong>
         likely to have evolved or transformed from the CLL/SLL clone. Therapy-related myeloid neoplasms are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">
          "Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8541716">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/687.html" rel="external">
          "Patient education: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6814180">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stepwise evolution
         </strong>
         – Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a lymphoid neoplasm characterized by the progressive accumulation of monoclonal functionally incompetent lymphocytes in the peripheral blood, lymph nodes, and spleen. The term CLL is used when the disease manifests primarily in the blood, whereas the term SLL is used when involvement is primarily nodal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pathogenesis of CLL/SLL is a complex, multistep process due to changes within the evolving B cell and its microenvironment  (
         <a class="graphic graphic_figure graphicRef85975" href="/z/d/graphic/85975.html" rel="external">
          figure 1
         </a>
         ). This process begins the development of a small, asymptomatic B cell clone, known as monoclonal B cell lymphocytosis (MBL). Evolution can be conceptualized as a sequential process, with a minority of cases progressing at each step (see
         <a class="local">
          'Disease evolution from monoclonal B cell lymphocytosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Establishment of MBL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Progression to asymptomatic CLL/SLL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Progression to symptomatic CLL/SLL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transformation to a more aggressive histology
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cell of origin
         </strong>
         – While CLL/SLL cells look like mature small lymphocytes seen in the peripheral blood of normal individuals, they are functionally incompetent clonal B cells with arrested development likely from the "activated, antigen-experienced" B cell subset. The cell of origin likely differs between cases with and without mutated immunoglobulin heavy chain variable region (IGHV) genes (see
         <a class="local">
          'The CLL cell'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CLL with unmutated IGHV – Likely derived from pre-germinal center (unmutated) mature CD5+ B cells; cells are polyreactive, capable of binding multiple epitopes that can result in sustained B cell receptor (BCR) signalling; clones expand more rapidly, and the clinical course is more aggressive.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CLL with mutated IGHV – Likely derived from post-germinal center B cells; cells have a narrow antigen specificity (more anergic) and dampened BCR signalling; clones expand more slowly, and the clinical course is more indolent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Apoptosis and proliferation impact kinetics
         </strong>
         – CLL/SLL cells can exhibit impaired apoptosis and increased proliferation. The kinetic balance between these impacts disease tempo.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired apoptosis – Malignant cells accumulate at least partly due to their inability to undergo apoptosis, often due to overexpression of the antiapoptotic protein B cell leukemia/lymphoma 2 (BCL2). (See
         <a class="local">
          'Upregulation of BCL2 proto-oncogene'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased proliferation – Proliferation rates are variable; some cases exhibit exponential growth with short lymphocyte doubling times and rapidly progressive disease, while others demonstrate a logistic growth that slows and stabilizes. Proliferation is impacted by genetic features (eg, IGHV mutation status), BCR signaling, and interactions with the tumor microenvironment and/or antigens. (See
         <a class="local">
          'Antigen-independent BCR signaling'
         </a>
         above and
         <a class="local">
          'Tumor microenvironment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune system abnormalities
         </strong>
         – Patients with CLL/SLL have abnormal cellular and humoral-mediated immune responses due to qualitative and quantitative defects in immune effector cells. In addition, a subset experience autoimmune phenomena. (See
         <a class="local">
          'Defective B and T cell function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic changes and signaling pathways implicated
         </strong>
         – Genetic abnormalities are present in the vast majority of CLL tumors at diagnosis, and additional genetic abnormalities are acquired with disease evolution. Some appear to play a role in the pathogenesis and evolution of CLL/SLL. The deleted region in CLL/SLL with del(13q14) contains micro-RNA that control the expression of multiple genes, including the gene which encodes BCL2. Deletion 17p,
         <em>
          TP53
         </em>
         mutation, and deletion 11q can all lead to impaired DNA damage response. (See
         <a class="local">
          'Genetic abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Signaling pathways that are key to understanding the biology of CLL/SLL from a clinical perspective include the following (see
         <a class="local">
          'Aberrant signaling pathways'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antigen-independent BCR signaling – Constitutive activation of BCR results in intracellular signals that promote growth, survival, differentiation, and migration. (See
         <a class="local">
          'Antigen-independent BCR signaling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Upregulation of BCL2 – BCL2 is an antiapoptotic protein; when overexpressed, CLL cells do not respond appropriately to signals that should induce apoptosis. (See
         <a class="local">
          'Upregulation of BCL2 proto-oncogene'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired DNA damage response – CLL/SLL tumors with deletion 17p,
         <em>
          TP53
         </em>
         mutation, or deletion 11q are missing mechanisms to induce cell cycle arrest and apoptosis in response to stressors such as chemotherapy-induced DNA damage. (See
         <a class="local">
          'Impaired DNA damage response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most CLL tumors have thousands of somatic gene mutations. Of these, four are present at diagnosis in &gt;5 percent of patients:
         <em>
          TP53, ATM, NOTCH1,
         </em>
         and
         <em>
          SF3B1
         </em>
         . Many of the other mutations seen in CLL tumors are involved in a limited number of cellular signaling pathways. (See
         <a class="local">
          'Gene mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor microenvironment
         </strong>
         – CLL cells both influence the composition of the cells around them, and they are highly dependent upon signals from these cells for their own survival and proliferation. Bidirectional interactions occur between CLL cells and the extracellular matrix, T cells, nurse-like cells (monocyte derived macrophages), stromal follicular dendritic cells, and other stromal cells. (See
         <a class="local">
          'Tumor microenvironment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1603885">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <strong>
         </strong>
         UpToDate editorial staff acknowledges Michael J Keating, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009; 146:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009; 27:3959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fazi C, Scarfò L, Pecciarini L, et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 2011; 118:6618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood 2012; 119:4358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CJ. CLL clonal heterogeneity: an ecology of competing subpopulations. Blood 2012; 120:4117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123:2139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 2016; 127:2122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knisbacher BA, Lin Z, Hahn CK, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet 2022; 54:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102:1515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99:4087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103:4389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kipps TJ, Tomhave E, Chen PP, Carson DA. Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med 1988; 167:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kipps TJ, Tomhave E, Pratt LF, et al. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1989; 86:5913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81:2475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antin JH, Emerson SG, Martin P, et al. Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol 1986; 136:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bofill M, Janossy G, Janossa M, et al. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985; 134:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982; 155:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004; 103:2337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadol N, Ault KA. Phenotypic and functional characterization of human Leu1 (CD5) B cells. Immunol Rev 1986; 93:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe M, Tominaga K, Wakasa H. Phenotypic characterization of human B-lymphocyte subpopulations, particularly human CD5+ B-lymphocyte subpopulation within the mantle zones of secondary follicles. Leukemia 1994; 8:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inghirami G, Foitl DR, Sabichi A, et al. Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. Blood 1991; 78:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dighiero G. Biology of the neoplastic lymphocyte in B-CLL. Baillieres Clin Haematol 1993; 6:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008; 112:4213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruber M, Bozic I, Leshchiner I, et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature 2019; 570:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy EJ, Neuberg DS, Rassenti LZ, et al. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia 2017; 31:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herndon TM, Chen SS, Saba NS, et al. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia 2017; 31:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger JA, Li KW, Keating MJ, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2017; 2:e89904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer 2015; 121:2883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dighiero G. An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL. Nouv Rev Fr Hematol 1988; 30:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majumdar G, Brown S, Slater NG, Singh AK. Clinical spectrum of autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Leuk Lymphoma 1993; 9:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005; 105:2007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plater-Zyberk C, Maini RN, Lam K, et al. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum 1985; 28:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin K, Manocha S, Harris RJ, et al. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003; 102:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99:2262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101:4952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119:4467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007; 109:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorsélius M, Kröber A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006; 107:2889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athanasiadou A, Stamatopoulos K, Gaitatzi M, et al. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica 2008; 93:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013; 27:2196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013; 121:4902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadeu F, Royo R, Clot G, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood 2021; 137:2935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood 2021; 137:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fegan C, Robinson H, Thompson P, et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995; 9:2003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24:4634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006; 132:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grubor V, Krasnitz A, Troge JE, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009; 113:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knuutila S, Elonen E, Teerenhovi L, et al. Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. N Engl J Med 1986; 314:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsagiopoulou M, Chapaprieta V, Duran-Ferrer M, et al. Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. Haematologica 2020; 105:2864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica 2020; 105:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lampson BL, Gupta A, Tyekucheva S, et al. Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia. J Clin Oncol 2023; 41:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118:6904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn CN, Scott HS. Spliceosome mutations in hematopoietic malignancies. Nat Genet 2011; 44:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrie CH. MicroRNAs and haematology: small molecules, big function. Br J Haematol 2007; 137:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 2009; 114:4761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114:3872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 2006; 33:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004; 101:11755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109:4944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013; 122:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mraz M, Chen L, Rassenti LZ, et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 2014; 124:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67:8433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dühren-von Minden M, Übelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012; 120:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vardi A, Agathangelidis A, Sutton LA, et al. Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. Cancer Res 2014; 74:4211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mockridge CI, Potter KN, Wheatley I, et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007; 109:4424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82:1820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papakonstantinou G, Verbeke C, Hastka J, et al. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hockenbery D, Nuñez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricciardi MR, Petrucci MT, Gregorj C, et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol 2001; 113:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992; 89:7491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001; 264:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood 2013; 121:4036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaramillo S, Agathangelidis A, Schneider C, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica 2020; 105:2598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta 2016; 1863:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna BS, Öztürk S, Seiffert M. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia. Mol Immunol 2019; 110:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsay AG, Evans R, Kiaii S, et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013; 121:2704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna BS, Roessner PM, Yazdanparast H, et al. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia 2019; 33:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llaó Cid L, Hanna BS, Iskar M, et al. CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. Leuk Lymphoma 2020; 61:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Matteis S, Molinari C, Abbati G, et al. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. J Transl Med 2018; 16:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dianzani U, Omedè P, Marmont F, et al. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. Blood 1994; 83:2198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 2001; 112:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopoulos P, Pfeifer D, Bartholomé K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117:3836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görgün G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöllkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007; 121:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giles FJ, O'Brien SM, Keating MJ. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998; 25:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017; 129:3362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 2018; 32:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379:2517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 2019; 380:2225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007; 139:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solh M, Rai KR, Peterson BL, et al. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma 2013; 54:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjeldsberg CR, Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia. Cancer 1981; 48:2447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation. Br J Haematol 1986; 64:77.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4539 Version 54.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438485" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620484" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18687638" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21876118" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22422819" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Monoclonal B-cell lymphocytosis: right track or red herring?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23160186" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : CLL clonal heterogeneity: an ecology of competing subpopulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24501221" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26200345" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Non-coding recurrent mutations in chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26466571" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mutations driving CLL and their evolution in progression and relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26837699" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35927489" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Molecular map of chronic lymphocytic leukemia and its impact on outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9788964" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12010811" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14962897" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Chronic lymphocytic leukemia: revelations from the B-cell receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3127527" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2503826" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8490163" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23091163" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cellular origin and pathophysiology of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2934473" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3871452" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Human B cell development. II. Subpopulations in the human fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6977012" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091358" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630808" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3096877" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phenotypic and functional characterization of human Leu1 (CD5) B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7516026" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phenotypic characterization of human B-lymphocyte subpopulations, particularly human CD5+ B-lymphocyte subpopulation within the mantle zones of secondary follicles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1715792" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8038491" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Biology of the neoplastic lymphocyte in B-CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18708628" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31142838" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Growth dynamics in naturally progressing chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3954968" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15711642" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28115735" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28074063" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28138560" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25931291" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11472353" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16616071" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Infectious complications of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3065729" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482530" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8477195" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical spectrum of autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284121" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3899124" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12869492" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11877310" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12586612" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15057307" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22415752" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16985177" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16317103" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18310544" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23558524" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23637131" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33211804" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32992344" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609709" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17008705" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136261" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Genomic aberrations and survival in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16487171" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18922857" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3081810" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12434020" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20060366" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33256389" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22150006" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33054046" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36315919" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22077063" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23086750" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22039264" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22200771" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Spliceosome mutations in hematopoietic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22158541" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17539773" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : MicroRNAs and haematology: small molecules, big function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19745066" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19717645" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16616063" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251535" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284443" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17327404" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23821659" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24787006" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17823410" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22096249" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22885698" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22715122" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The B-cell receptor signaling pathway as a therapeutic target in CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25074616" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255355" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8104532" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380403" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20940416" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2250705" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380404" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1933891" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Participation of p53 protein in the cellular response to DNA damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1323840" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11237523" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Regulation of p53 function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440242" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9843217" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : ATM associates with and phosphorylates p53: mapping the region of interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33131249" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26193078" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29173971" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23247726" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23325833" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30267008" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31519123" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29925389" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7909242" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11298591" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21270444" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15965501" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17351903" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Risk of second cancer after chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482533" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Chronic lymphocytic leukemia in (Richter's) transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23782158" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28473407" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28592889" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30501481" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31166681" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17910629" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22897733" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7296493" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Prolymphocytic transformation of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3463362" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
